PDCD1 and melanoma: Several studies confirmed that increased mutational burdens were associated with higher response rates in patients with non-small-cell lung cancer (NSCLC) or melanoma treated with anti–PD-1 and anti-CTLA-4 antibodies, demonstrating the feasibility of using the TMB as a biomarker for patient selection.